{'52WeekChange': 0.057419896,
 'SandP52WeekChange': None,
 'address1': '400 Technology Square',
 'address2': '4th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 14.84,
 'askSize': 1200,
 'averageDailyVolume10Day': 939075,
 'averageVolume': 1150292,
 'averageVolume10days': 939075,
 'beta': 2.095798,
 'beta3Year': None,
 'bid': 14.23,
 'bidSize': 800,
 'bookValue': 3.01,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 14.6,
 'dayLow': 13.75,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -6.067,
 'enterpriseToRevenue': 69.011,
 'enterpriseValue': 1191344896,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '617 349 0707',
 'fiftyDayAverage': 16.458857,
 'fiftyTwoWeekHigh': 27.82,
 'fiftyTwoWeekLow': 9.74,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 82761034,
 'forwardEps': -2.09,
 'forwardPE': -6.8564596,
 'fromCurrency': None,
 'fullTimeEmployees': 203,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.0404,
 'heldPercentInstitutions': 1.00971,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/epizyme.com',
 'longBusinessSummary': 'Epizyme, Inc., a late-stage biopharmaceutical '
                        'company, discovers, develops, and commercializes '
                        'novel epigenetic medicines for patients with cancer '
                        'and other diseases primarily in the United States. '
                        "The company's lead products candidate is "
                        'tazemetostat, an inhibitor of the EZH2 histone '
                        'methyltransferase, which is in the Phase II clinical '
                        'trial for patients with relapsed or refractory '
                        'non-hodgkin lymphoma (NHL); Phase II clinical trial '
                        'for relapsed or refractory patients with mesothelioma '
                        'characterized by BAP1 loss-of-function; and Phase II '
                        'clinical trial for adults and Phase I clinical trial '
                        'for children with epithelioid sarcoma and other '
                        'INI1-negative solid tumors. It also develops '
                        'tazemetostat in combination with R-CHOP that is in '
                        'the Phase Ib/II clinical trials in elderly patients '
                        'with DLBCL; and tazemetostat in combination with '
                        'PD-L1 inhibitor, which is in the Phase Ib/II clinical '
                        'trials for the treatment of patients with relapsed or '
                        'refractory metastatic non-small cell lung cancer. In '
                        'addition, the company is developing EZM8266, a G9a '
                        'inhibitor that is in the Phase 1 study for the '
                        'treatment of sickle cell disease; pinometostat, which '
                        'is in the preclinical studies stage for the treatment '
                        'of acute myeloid leukemia and acute lymphoblastic '
                        'leukemia; PRMT5 inhibitor that is in Phase II '
                        'clinical trial for patients with solid tumors and '
                        'NHL; and PRMT1 inhibitor, which is in the Phase 1 '
                        'clinical trial. Epizyme, Inc. has collaboration '
                        'agreements with Celgene Corporation; Genentech Inc.; '
                        'Glaxo Group Limited; Boehringer Ingelheim '
                        'International GmbH; Roche Molecular Systems, Inc.; '
                        'Lymphoma Study Association; and Eisai Co. Ltd. The '
                        'company was founded in 2007 and is headquartered in '
                        'Cambridge, Massachusetts.',
 'longName': 'Epizyme, Inc.',
 'market': 'us_market',
 'marketCap': 1448204160,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_54339075',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -191892992,
 'nextFiscalYearEnd': 1640908800,
 'open': 13.93,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.16,
 'phone': '617 229 5872',
 'previousClose': 14.18,
 'priceHint': 2,
 'priceToBook': 4.7607975,
 'priceToSalesTrailing12Months': 83.89064,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 14.6,
 'regularMarketDayLow': 13.75,
 'regularMarketOpen': 13.93,
 'regularMarketPreviousClose': 14.18,
 'regularMarketPrice': 13.93,
 'regularMarketVolume': 832205,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 101061000,
 'sharesPercentSharesOut': 0.1093,
 'sharesShort': 11041686,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 7636461,
 'shortName': 'Epizyme, Inc.',
 'shortPercentOfFloat': 0.1478,
 'shortRatio': 6.26,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'EPZM',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.04,
 'twoHundredDayAverage': 18.801655,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'df4243f0-ec53-31f7-8399-4c1b724aec54',
 'volume': 832205,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.epizyme.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02139'}